F]AH111585) for PET imaging of angiogenesis in melanoma and renal tumors and compare with tumor integrin expression.
Methods Eighteen evaluable patients with solid tumors ≥2.0 cm underwent [ 18 F]fluciclatide PET/CT. All patients underwent surgery and tumor tissue samples were obtained. Immunohistochemical (IHC) staining with mouse monoclonal antibodies and diaminobenzidine (DAB) was applied to snap-frozen tumor specimens, and additional IHC was done on formalin-fixed paraffin-embedded samples. DAB optical density (OD) data from digitized whole-tissue sections were compared with PET SUV 80% max , and Patlak influx rate constant (K i ) data, tumor by tumor. Results Tumors from all 18 patients demonstrated measurable [ 18 F]fluciclatide uptake. At the final dynamic time-point (55 min after injection), renal malignancies (in 11 patients) demonstrated an average SUV 80% max of 6.4±2.0 (range 3.8 -10.0), while the average SUV 80% max for metastatic melanoma lesions (in 6 patients) was 3.0 ± 2.0 (range 0.7 -6.5). There was a statistically significant difference in [ 18 F]fluciclatide uptake between chromophobe and nonchromophobe renal cell carcinoma (RCCs, with SUV 80% max of 8.2±1.8 and 5.4±1.4 (P= 0.020) and tumor-to-normal kidney (T/N) ratios of 1.5± 0.4 and 0.9±0.2, respectively (P=0.029). The highest Pearson's correlation coefficients were obtained when comparing Patlak K i and α v β 5 OD when segregating the patient population between melanoma and RCC (r=0.83 for K i vs. melanoma and r=0.91 for K i vs. RCC). SUV 80% max showed a moderate correlation with α v β 5 and α v β 3 OD. Conclusion [ 18 F]Fluciclatide PET imaging was well tolerated and demonstrated favorable characteristics for imaging α v β 3 and α v β 5 expression in melanoma and RCC. Higher uptake was observed in chromophobe than in nonchromophobe RCC. [ Introduction Tumor-induced angiogenesis involves numerous signaling pathways mediated by growth factors, cellular receptors and adhesion molecules [1] . The integrins, α v β 3 and α v β 5 , are cell adhesion molecules implicated in the formation of vascular endothelial cells and expressed on tumor cell surfaces [2] . They contain a specific peptidebinding pocket with high affinity attachment for the arginine-glycine-aspartate (RGD) tripeptide sequence [3] . Because they are expressed in abundance on the surface of angiogenic endothelial cells, these integrins and their binding ligand, RGD, are attractive targets for therapy and imaging.
The advance in antiangiogenic therapeutics has given impetus to the development of angiogenesis imaging agents. Various radiolabeled RGD ligands have been created for integrin imaging [4, 5] but have not progressed as commercial products and therefore have limited availability in the clinic.
Renal cell cancer is the 12th most common cancer in the world and melanoma is the 19th according to the International Agency for Research on Cancer [6] . Melanoma is an aggressive malignancy and usually fatal with metastasis. Renal cell carcinoma (RCC) in the metastatic setting is similarly challenging with a poor prognosis. Angiogenesis is implicated in tumor growth and spread of many cancers, including melanoma and RCC and thus agents to disrupt this process have been tested in both diseases with great interest. Intetumumab and cilengitide, inhibitors of α v β 3 and α v β 5 integrins, have been studied in melanoma [7, 8] . Several antiangiogenic agents are used against metastatic RCC and include tyrosine kinase inhibitors, antivascular endothelial growth factor (VEGF) antibodies and mammalian target of rapamycin inhibitors. Many clinicians point to a need for functional imaging over anatomic imaging to accurately assess response to these therapies and this would benefit from an imaging tool targeting integrins [9] .
The purpose of our study was to examine the ability of the integrin-targeting agent, [ 18 F]fluciclatide (formerly known as [ 18 F]AH111585), to detect and measure α v β 3 and α v β 5 expression in melanoma and RCC, diseases known to exhibit these integrins. To our knowledge, studies on these specific groups with this tracer have not been previously published. [ 18 F]Fluciclatide is a small synthetic cyclic peptide configured to bind with high affinity to the RGD binding site of α v β 3 and α v β 5 integrins [10] . We describe here the in vivo pharmacokinetics of [ 18 F]fluciclatide and evaluate the correlations of its uptake and retention with tissue biomarkers of integrin expression.
Materials and methods

Patient population and study design
This was a HIPAA-compliant, prospective, single-institution study, approved by the local Institutional Review Board. Inclusion criteria included adults who had been previously diagnosed with metastatic malignant melanoma, or primary or metastatic renal tumor, with a target tumor lesion >2.0 cm, scheduled for therapeutic resection or biopsy. Eighteen evaluable patients (7 women, 11 men; age 51±10 years, range 24 -62 years) were examined with [ Table 1 . Of the 18 patients, 17 were imaged on a Philips Gemini TF PET/CT scanner in 3-D time of flight acquisition mode [11] and one was imaged on a GE LS Discovery scanner in 2-D acquisition mode. The images were reconstructed using the default row-action maximum-likelihood algorithm (RAMLA) iterative reconstruction and ordered-subsets expectation maximization (OSEM), respectively [12] , with standard corrections for randoms, scatter, attenuation, and normalization.
[
18 F]Fluciclatide was synthesized by a commercial PET agent provider (Cardinal Health, Greenbelt, MD) under Good Manufacturing Practices (GMP) conditions according to previously published methods [13] . Blood samples were taken for analysis of preformed antibodies against fluciclatide prior to imaging -none was identified. No specific patient preparation was undertaken prior to imaging. Patients received a single bolus dose intravenous injection of [ 18 F]fluciclatide with a maximum total activity of 373.7 MBq (range 126.9 -373.7 MBq). The estimated effective dose was approximately 26 μSv/MBq [14] , resulting in a mean administered dose of 8.8 mSv.
The dynamic PET acquisition was initiated with a 30-s background frame, immediately after which the [ 18 F]fluciclatide was injected. The dynamic PET acquisition was performed for 60 min after injection (p.i.) with the target lesion within the field of view (FOV) using the following acquisition protocol (12 × 5-s frames, 6 × 10-s frames, 6 × 30-s frames, 5 × 2-min frames, 5 × 3-min, and 3 × 10-min frames). The patient was then taken off the scanner bed for a break and was encouraged to void. After voiding, the patient was repositioned on the scanner bed and a static torso PET acquisition (from the ears to the mid-thighs with 2 min per bed position) was initiated at about 80 min p.i. (range 71 -91 min p.i.). Corresponding low-dose transmission CT scans (60 mA, 120 kVp) were acquired before each PET emission scan.
Image analysis
Images were prospectively assessed by two experienced nuclear medicine physicians, blinded to the histopathology results. For most of the eight patients with RCC, MRI images were also available and fused with the PET/CT images for improved anatomic correlation to tumor.
Only one lesion per subject, defined as the 'target lesion' was evaluated quantitatively. A volume of interest (VOI) was defined as the mean of the hottest 20 % of all pixels in the target lesion identified (80 % thresholded maximum standardized uptake value, SUV 80% max ) using MIM 5.2 (MIM Software, Cleveland, OH) and applied to the dynamic and static PET data. A VOI to estimate the blood pool was drawn manually as a spherical volume within a homogeneous location (>4 mm 3 ) within the largest vascular structure (typically the aorta) for the SUV BP within the dynamic image FOV to estimate a vascular input function. Similarly, VOIs within the muscle (about 2.5 cm in diameter), and normal kidney parenchyma (>4 mm in diameter) contralateral to the tumor site were obtained to evaluate target lesions in relation to background uptake. The static SUV 80% max was obtained at 55 min p.i. because it is more representative of maximum radiotracer accumulation, based on previously published kinetics of [ 18 F]fluciclatide determined in a phase 1 study [10] . Tumor-to-blood (T/B) and tumor-to-muscle (T/M) ratios were also calculated at the same time-point.
Time-activity curves (TACs) representing SUV 80% max for each target lesion and SUV BP were used in graphical analyses as described by Patlak and Blasberg [15] to assess irreversible tracer binding. Image-derived blood curves (SUV mean ) were converted into metabolitecorrected plasma curves using group average curves of the plasma-to-blood ratio and percent intact radioligand calculations based on previous data with [ 18 F]fluciclatide [16] . These were used as subject-specific estimates of plasma input functions in the Patlak analysis. The SUV mean attributable to the fractional blood volume in the tissue was estimated by linear least squares fitting for the first 2 min and then subtracted from the tissue SUV mean . The tissue data corrected for fractional blood volume were fitted to a straight line for the time interval from 12 min (range 4.5 -21 min) to 60 min. In the Patlak plot, the slope of the linear portion represents the tracer influx rate constant (K i ). 
Results
Clinical findings [
18 F]Fluciclatide injections were well tolerated by all patients without any radiotracer-related adverse events. One patient developed thrombocytopenia (<5,000 platelets/ ml), which subsequently proved to be unrelated to [ 18 F]fluciclatide administration and was attributed to prior treatments. Anti-fluciclatide antibodies were negative. Histopathology was assessed in 18 tumor foci: six patients presented with metastatic malignant melanoma ( Figs. 1 and 2) , one patient had a large renal oncocytoma, ten patients had primary RCC (six nonchromophobe clear-cell carcinoma and four chromophobe-type; Fig. 3 ), and one patient had metastatic clear-cell (nonchromophobe) RCC within a large retroperitoneal lymph node.
All evaluable malignant target lesions (18 lesions) showed [ 4 , whereas those with metastatic melanoma showed variable uptake with an average SUV 80% max of 3.0±2.0 (range 0.7 -6.5), a T/B ratio of 0.7±0.4 and a T:M ratio of 4.5±3.9. Interestingly, the lowest SUV 80% max value (0.7) was obtained from a metastatic brain lesion, which showed low radiotracer uptake at earlier time points that increased with time, ultimately reaching an SUV 80% max of 1.54 at 125 min p.i. There was a statistically significant difference in [ 
Discussion
This study demonstrated the feasibility and tolerability of [ 18 F]fluciclatide PET imaging in patients with metastatic melanoma or kidney tumors. Our data corroborated the findings of previous studies in humans with [10] , showing favorable tumortargeting properties, including rapid and high tumor uptake, quick clearance from blood and normal tissues, and high T/M ratios, resulting in favorable image contrast and tumor delineation.
Clinical PET studies with [
18 F]fluciclatide were initially performed in healthy volunteers to assess safety, radiation dosimetry and biodistribution [14] , and later in patients with breast or lung cancer to evaluate kinetic modeling and estimate tumor/background specific binding [10, 18] . In our cohort, a high detection rate was found, identifying all tumors (in 18 patients) consistent with previous results in which all 18 lesions in seven patients with advanced metastatic breast cancer were detected by [ 18 F]fluciclatide PET imaging [10] . The malignant lesions in our cohort of patients showed heterogeneous tracer uptake with an average SUV 80% max of 6.8± 3.2 that was independent of tumor size. [ 18 F]Fluciclatide showed significantly higher radiotracer uptake in Distinguishing between the two RCC types is significant in terms of patient prognosis and therapeutic options. α v β 3 integrin expression also showed a strong correlation with SUV 80% max in chromophobe and nonchromophobe RCC (r = 0.93 and r = 0.002; P=0.066). The high r value for the correlation between SUV 80% max and α v β 3 may have been due to the small sample of patients with chromophobe RCC (four patients). Surprisingly high uptake (SUV 80% max 9.20, T/N ratio 1.7) was seen in the single oncocytoma. This is interesting because previous research has suggested a histopathological link between renal oncocytoma and chromophobe RCC [19] . In the single patient with brain metastases, [ 18 F] fluciclatide retention was not found in normal brain but was localized in tumor at the site of disruption of the blood-brain barrier -a finding also reported with [ 18 F]galacto-RGD in patients with glioblastoma [20] .
The ability of [ 1 8 F] fluciclatide to target the neovasculature via the α v β 3 and α v β 5 integrins expressed on endothelial cells was initially reported by Pasqualini et al. [21] , who demonstrated that tumor endothelial cells are targeted by the RGD sequence. Subsequent imaging studies focused mostly on α v β 3 while we chose to additionally measure α v β 5 expression. This was supported by an in vitro study [10] showing that fluciclatide binding is about two orders of magnitude stronger to α v β 5 than to α v β 3 . A significant correlation between α v β 3 expression and radiotracer uptake with [ 18 F]galacto-RGD PET was later demonstrated in murine tumor models [22, 23] [26] and head and neck carcinomas [27] . Beer et al. [25] used a semiquantitative method of correlation expressing staining intensity as 0, +1, +2 or +3. In the current study, a quantitative rather than semiquantitative IHC analysis was performed using continuous OD measurements as described by Spector et al. [28] yielding similar but less highly correlated results. This could have been due to artifacts from processing or limited sampling of tumor as will be discussed below.
Positive strong to moderate correlations were observed between each of the PET parameters (K i , and SUV 80% max ) and α V β 5 and α V β 3 expression in patients with metastatic melanoma and renal tumors. For renal tumors, these correlations were seen in samples of both chromophobe and nonchromophobe tumors. The strongest correlation was seen with chromophobe carcinomas between K i and α V β 3, which are usually highly vascular tumors, b ut are l ess commo n t han clear-ce ll (nonchromophobe) carcinomas of the kidney. This observation has potential therapeutic implications for the use of anti-integrin agents in chromophobe carcinomas.
Regarding melanoma, our results are concordant with those of previously published preclinical and clinical studies that showed high levels of α v β 3 integrin expression in melanoma [29, 30] , contrary to lower integrin expression levels reported in RCC [31, 25] .
There are some potential limitations of this study. First, we studied a small number of patients. Nonetheless, the observed difference in uptake between chromophobe and nonchromophobe renal tumors was sufficient to achieve significance. Second, we employed digital histopathology of whole-tissue sections rather than more subjective readings of smaller FOVs, hoping for better reproducibility. Third, IHC of frozen sections is susceptible to artefacts due to tissue processing and freezethaw damage, potentially reducing the expected correlation between integrin expression and IHC positivity. Fourth, we employed a single IHC slide per tumor from a random position within the tumor rather than probing multiple sites or the site of greatest [ 18 F]fluciclatide uptake. Fifth, the single IHC slides and the PET images were not spatially coregistered, and hence the IHC slide may not be representative of the site of highest [ 18 F]fluciclatide uptake. Finally, we did not measure MVD, therefore we could not estimate the contribution of integrin measured in the tumor vasculature to integrin uptake in the entire tumor.
The next promising application of [ 18 F]fluciclatide PET imaging would be to determine its utility in monitoring the status of α v β 3 and α v β 5 expression before and during antiangiogenic therapies [32] . A number of antiangiogenic agents are now approved for use or are in late phase clinical trials [33] [34] [35] [36] .
Conclusion
The favorable imaging and tolerability characteristics of [ 
